NYSE:NAVB Navidea Biopharmaceuticals (NAVB) Stock Price, News & Analysis → Free report reveals 5 stocks that can double in 2024 (From TradingTips) (Ad) Free NAVB Stock Alerts $0.04 0.00 (0.00%) (As of 05/10/2024 ET) Add Compare Share Share Today's Range$0.04▼$0.0450-Day Range$0.03▼$0.0552-Week Range$0.02▼$0.17Volume9,365 shsAverage Volume66,293 shsMarket Capitalization$3.60 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsSocial MediaStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsSocial Media Get Navidea Biopharmaceuticals alerts: Email Address Ad WealthPressBuy Friday. Sell Monday. A 35 year old man from central Florida has stumbled on one of the best strategies we’ve seen in a long time. For the last 30 months his “Friday to Monday” trading strategy has maintained a 71% win rate on more than 350 trades. That includes multiple big time winners like 82% from Adobe… 77% from Palo Alto… But also a barrage of smaller winners like 20% from AMC… Each of which were opened on a Friday afternoon and closed the very next Monday morning. As you’ll see in his brand new video, this strange strategy has given him the ability to capture big time market moves over the weekend.Check it out, simply follow this link here. About Navidea Biopharmaceuticals Stock (NYSE:NAVB)Navidea Biopharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of precision immunodiagnostic agents and immunotherapeutics. It operates in two segments, Diagnostic Substances and Therapeutic Development Programs. The company develops Manocept platform to target the CD206 mannose receptor expressed on activated macrophages for a range of diagnostic modalities, including single photon emission computed tomography, positron emission tomography (PET), gamma-scanning, and intra-operative and/or optical-fluorescence detection, as well as delivery of therapeutic compounds that target macrophages, and immune-and inflammation-involved diseases. It develops NAV3-31, which has completed Phase IIb clinical trials for evaluating imaging repeatability, reproducibility, and stability, as well as the capacity of Tc99m tilmanocept imaging for treatment of anti-tumor necrosis factor alpha therapy in patients with moderate to severe rheumatoid arthritis (RA); NAV3-35 that is in a Phase IIb clinical trial for RA imaging; NAV3-33, which is in Phase III clinical trial for RA; and NAV3-32, which is Phase 2b trial for RA-involved joints. The company is also developing Tc99m tilmanocept for cardiovascular, kaposi's sarcoma, tuberculosis, and other immunotherapeutic applications. The company was formerly known as Neoprobe Corporation and changed its name to Navidea Biopharmaceuticals, Inc. in January 2012. Navidea Biopharmaceuticals, Inc. was incorporated in 1983 and is headquartered in Dublin, Ohio.Read More NAVB Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart NAVB Stock News HeadlinesMay 7, 2024 | americanbankingnews.comStockNews.com Initiates Coverage on Navidea Biopharmaceuticals (NYSE:NAVB)May 3, 2024 | nasdaq.comDay One Biopharmaceuticals, Inc. Common Stock (DAWN)May 12, 2024 | Allegiance Gold (Ad)Does this make you sick?The US Dollar Is "Finished" A deteriorating economy, global instability, and a weakened banking system have pushed the U.S. financial system to the brink, imperiling the value of your savings and investments.February 23, 2024 | benzinga.comNavidea Biopharmaceutical Stock (OTC:NAVB), Short Interest ReportFebruary 22, 2024 | benzinga.comNavidea Biopharmaceutical Stock (OTC:NAVB) Dividends: History, Yield and DatesFebruary 22, 2024 | benzinga.comNavidea Biopharmaceutical Stock (OTC:NAVB) Insider TradesJanuary 29, 2024 | bizjournals.comCentral Ohio public company voluntarily deregisters stockJanuary 26, 2024 | finance.yahoo.comNavidea Biopharmaceuticals, Inc. Files Form 15 to Voluntarily Deregister and Suspend its SEC Reporting ObligationsMay 12, 2024 | Crypto Swap Profits (Ad)He Is Giving Away BitcoinAnd my special guest is willing to give you $10 in Bitcoin (BTC) if you take it seriously. Right now is a very important time to pay attention to what we are doing and what is happening. If you wait... it will be too late. This week we are holding several workshops and if you attend and pay attention my special guest is going to send you $10 in Bitcoin.January 26, 2024 | finance.yahoo.comNavidea Biopharmaceuticals, Inc. Files Form 15 to Voluntarily Deregister and Suspend its SEC Reporting ObligationsJanuary 11, 2024 | investing.comSuzhou Zelgen Biopharmaceuticals Co Ltd (688266)December 1, 2023 | msn.comNavidea settles litigation with Capital Royalty, stock rallies 30%December 1, 2023 | markets.businessinsider.comNavidea Biopharmaceuticals, CRG Settle All Ongoing LitigationNovember 1, 2023 | morningstar.comNavidea Biopharmaceuticals Inc NAVBOctober 26, 2023 | investing.comNavidea Biopharmaceuticals faces delisting from NYSE American, plans to move to OTC marketsOctober 6, 2023 | bizjournals.comNYSE American halts trading on Navidea stock after delisting recommendedOctober 5, 2023 | finance.yahoo.comNavidea Biopharmaceuticals, Inc. Announces NYSE American’s Decision to Suspend Trading In Its Common StockOctober 5, 2023 | tmcnet.comNYSE American to Suspend Trading in Navidea Biopharmaceuticals, Inc. (NAVB)August 10, 2023 | finance.yahoo.comNavidea Biopharmaceuticals, Inc. NAVB Requests Oral Hearing With NYSE Hearing PanelAugust 1, 2023 | finance.yahoo.comNYSE American starts to delist Navidea stock, company to appealJuly 31, 2023 | benzinga.comWhy Navidea Biopharmaceuticals Shares Are NosedivingJuly 31, 2023 | finance.yahoo.comNavidea Biopharmaceuticals, Inc. Presses Ahead, Embraces OpportunitiesJuly 28, 2023 | finance.yahoo.comNavidea Biopharmaceuticals, Inc. Announces NYSE American Has Commenced Delisting Proceedings and Intent to Appeal NYSE American DeterminationJuly 28, 2023 | businesswire.comNYSE American to Commence Delisting Proceedings Against Navidea Biopharmaceuticals, Inc. (NAVB)July 28, 2023 | finance.yahoo.comNavidea Biopharmaceuticals, Inc. Hires Craig A. Dais, CPA as Chief Financial OfficerJuly 13, 2023 | finance.yahoo.comNavidea Biopharmaceuticals, Inc. Welcomes Dana J Moss, JD to Board of Directors; Amit Bhalla Steps DownJuly 6, 2023 | bizjournals.comDublin biotech proposes reverse stock split, stock-for-debt swapSee More Headlines Receive NAVB Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Navidea Biopharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/10/2021Today5/12/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNYSE SectorMedical Industry Diagnostic substances Sub-IndustryN/A Current SymbolNYSE:NAVB CUSIPN/A CIK810509 Webwww.navidea.com Phone614-793-7500Fax614-793-7522Employees11Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($0.06) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-15,180,000.00 Net MarginsN/A Pretax Margin-860,700.00% Return on EquityN/A Return on Assets-166.65% Debt Debt-to-Equity RatioN/A Current Ratio0.56 Quick Ratio0.51 Sales & Book Value Annual Sales$70,000.00 Price / Sales51.47 Cash FlowN/A Price / Cash FlowN/A Book Value($0.25) per share Price / Book-0.14Miscellaneous Outstanding Shares100,080,000Free Float56,367,000Market Cap$3.60 million OptionableNo Data Beta1.13 A Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for May 2024. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.Get This Free Report Key ExecutivesDr. Michael Sherman Blue F.A.C.E.P.M.D., Chief Medical OfficerKey CompetitorsMyMD PharmaceuticalsNASDAQ:MYMDVirax Biolabs GroupNASDAQ:VRAXBiomericaNASDAQ:BMRATrinity BiotechNASDAQ:TRIBLongeveronNASDAQ:LGVNView All Competitors NAVB Stock Analysis - Frequently Asked Questions How have NAVB shares performed in 2024? Navidea Biopharmaceuticals' stock was trading at $0.0552 at the beginning of 2024. Since then, NAVB stock has decreased by 34.8% and is now trading at $0.0360. View the best growth stocks for 2024 here. How were Navidea Biopharmaceuticals' earnings last quarter? Navidea Biopharmaceuticals, Inc. (NYSE:NAVB) released its quarterly earnings results on Wednesday, November, 10th. The company reported ($0.08) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.11) by $0.03. The business had revenue of $0.10 million for the quarter, compared to analyst estimates of $0.60 million. How do I buy shares of Navidea Biopharmaceuticals? Shares of NAVB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NYSE:NAVB) was last updated on 5/12/2024 by MarketBeat.com Staff From Our PartnersTech GIANT’s Plans to Revolutionize Crypto…Crypto 101 MediaThe ONE AI Stock to own now. (It’s not Nvidia.)Weiss RatingsCollapse of the Petrodollar Colonial MetalsHe Is Giving Away BitcoinCrypto Swap ProfitsGold Set to EXPLODE!Gold Safe ExchangeShocking: One AI startup's revenue could surge 4,735%Manward PressElon to Transform U.S. Economy? Porter & CompanyMissed NVDA? Buy this AI stock NOWChaikin Analytics Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Navidea Biopharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.